|Chemical and physical data|
|Molar mass||374.45 g·mol−1|
|3D model (JSmol)|
Glasdegib (PF-04449913) is an approved cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is overexpressed in many types of cancer. It inhibits smoothened receptor, as do most drug in its class.
Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib. Another is a combination trial of glasdegib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia. The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.
- "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
- "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
|This oncology article is a stub. You can help Wikipedia by expanding it.|